PDL BIOPHARMA INC COM - COM (Y104L) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / COM
Symbol
Y104L
Price per share
$2.47
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
11,641
Total reported value
$27,980
Share change
0
Number of holders
2
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

As of 31 Dec 2025, 2 institutional investors reported holding 11,641 shares of PDL BIOPHARMA INC COM - COM (Y104L).

Institutional Holders of PDL BIOPHARMA INC COM - COM (Y104L) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 11,641 $27,980 $2.43 2
2025 Q3 11,641 $27,980 $2.43 2
2025 Q2 11,674 $27,983 +$3 $2.40 3
2025 Q1 11,641 $27,980 $2.43 2
2024 Q4 11,641 $27,980 $2.43 2
2024 Q3 11,641 $27,980 $2.43 2
2024 Q2 11,641 $27,980 $2.43 2
2024 Q1 11,641 $27,980 -$102,270 $2.43 2
2023 Q4 53,046 $130,250 $2.47 3
2023 Q3 53,046 $130,250 $2.47 3
2023 Q2 53,046 $130,250 +$103,781 $2.47 3
2023 Q1 11,029 $26,469 +$26,469 $2.40 1
2022 Q1 10,368 $27,000 $2.85 2
2021 Q4 0 $0 -$41,147,000 $2.47 0
2021 Q3 14,487,771 $41,147,000 +$83,000 $2.47 3
2021 Q2 14,454,212 $37,862,000 -$351,000 $2.55 2
2021 Q1 14,596,374 $36,738,000 -$67,591,445 $2.47 3
2020 Q4 42,093,400 $103,979,091 -$189,358,191 $2.47 30
2020 Q3 98,410,264 $309,535,197 +$8,132,941 $3.15 123
2020 Q2 95,629,140 $278,485,332 +$13,919,108 $2.91 126
2020 Q1 88,025,718 $654,040,259 -$12,561,473 $2.82 121
2019 Q4 98,114,970 $318,380,561 -$1,573,167 $3.24 138
2019 Q3 99,229,408 $214,317,494 -$15,871,926 $2.16 129
2019 Q2 105,799,957 $332,116,106 -$29,711,008 $3.14 136
2019 Q1 115,426,245 $429,384,343 -$13,663,123 $3.72 143
2018 Q4 119,650,114 $346,952,317 -$17,349,555 $2.90 144
2018 Q3 125,303,681 $329,394,575 -$2,079,428 $2.63 143
2018 Q2 126,868,405 $296,855,998 -$20,117,383 $2.34 150
2018 Q1 134,949,944 $396,719,811 -$17,260,696 $2.94 167
2017 Q4 141,918,625 $389,215,620 +$7,909,790 $2.74 178
2017 Q3 137,778,411 $466,925,783 +$27,938,054 $3.39 180
2017 Q2 129,785,647 $320,660,647 -$9,234,067 $2.47 160
2017 Q1 133,817,301 $303,707,293 +$43,340,422 $2.27 163
2016 Q4 130,000,949 $275,619,530 -$14,338,126 $2.12 181
2016 Q3 129,848,689 $434,588,981 +$13,867,107 $3.35 189
2016 Q2 125,886,121 $395,283,383 -$6,540,600 $3.14 191
2016 Q1 127,443,399 $424,229,640 -$26,278,429 $3.33 185
2015 Q4 134,930,115 $477,705,989 -$26,146,873 $3.54 193
2015 Q3 138,140,158 $694,939,041 -$49,522,483 $5.03 202
2015 Q2 147,156,556 $946,112,698 +$17,108,200 $6.43 198
2015 Q1 144,300,344 $1,015,473,018 -$106,825,098 $7.03 205
2014 Q4 158,915,436 $1,225,110,060 +$50,334,510 $7.71 216
2014 Q3 152,178,092 $1,136,714,292 +$54,472,639 $7.47 224
2014 Q2 144,200,694 $1,395,740,531 +$40,540,498 $9.68 219
2014 Q1 140,831,404 $1,170,261,130 +$43,236,003 $8.31 227